 CAMBRIDGE, Mass. BEIJING--BUSINESS WIRE--- BGNE BTKi--BeiGene NASDAQ: BGNE; HKEX: 06160, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA zanubrutinib has been approved in Australia for the treatment of adult patients with Waldenströms macroglobulinemia WM who have received at least one prior therapy or in first line treatment for patients unsuita 